摘要
目的观察阿替普酶静脉溶栓治疗急性脑梗死的疗效及安全性。方法选择2011—2014年确诊的急性脑梗死患者40例,分为阿替普酶静脉溶栓治疗组24例,对照组16例,比较2组溶栓前、溶栓后1d、溶栓后7d的NIHSS评分以及溶栓后3个月的mRS评分,并观察其不良反应。结果治疗组溶栓前与溶栓后7d的NIHSS评分与对昭组比较差异有统计学意义(P<0.05)。根据mRS评分,治疗后3个月,溶栓组预后良好13例(54.2%),对照组为7例(43.7%)。溶栓组1例出现症状性脑出血,治疗后恢复。结论在治疗时间窗内,阿替普酶静脉溶栓治疗急性脑梗死安全有效。
Objective To observe the efficacy and safety of intravenous thrombolysis with alteplase（rt‐PA） in the treat‐ment of acute cerebral infarction .Methods 40 patients with acute cerebral infarction from 2011 to 2014 were divided into the treatment group （24 cases） and the control group （16 cases） .The NIHSS scores were analyzed before thrombolysis and on the 1st and 7th day after thrombolysis ,and mRS scores were evaluated at 3 months after thrombolysis .The major adverse reac‐tions were also observed in this study .Results The NIHSS scores significantly decreased （P〈0 .05） on 7th day after throm‐bolysis compared with before thrombolysis in all 24 cases of the treatment group .According to mRS scores ,13 cases （54 .2% ） of the treatment group had good prognosis;while 7 cases （43 .7% ） of the control group had good prognosis .One patient recov‐ered from symptomatic cerebral hemorrhage after thrombolytic therapy .Conclusion In the treatment window ,rt‐PA throm‐bolysis may be an effective and safe therapy for the acute cerebral infarction .
出处
《中国实用神经疾病杂志》
2015年第20期11-12,共2页
Chinese Journal of Practical Nervous Diseases
关键词
急性脑梗死
阿替普酶
静脉溶栓
Acute cerebral infarction
rt-PA
Intravenous thrombolysis
